During the last three months, 11 analysts shared their evaluations of 10x Genomics (NASDAQ:TXG), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 3 | 2 | 5 | 0 | 1 |
Last 30D | 0 | 1 | 1 | 0 | 0 |
1M Ago | 3 | 0 | 2 | 0 | 0 |
2M Ago | 0 | 1 | 1 | 0 | 1 |
3M Ago | 0 | 0 | 1 | 0 | 0 |
Analysts have recently evaluated 10x Genomics and provided 12-month price targets. The average target is $26.0, accompanied by a high estimate of $46.00 and a low estimate of $16.00. A 35.0% drop is evident in the current average compared to the previous average price target of $40.00.
![1723575689_0.png](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240814/42281075-0-d8a70b155438fe920af8002a4164fd79.png/big)
Interpreting Analyst Ratings: A Closer Look
The analysis of recent analyst actions sheds light...
Login or create a forever free account to read this news
Sign up/Log in